iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Historical Holders from Q3 2020 to Q3 2025

Symbol
ITOS
CUSIP
46565G104
Type / Class
Equity / Common stock, par value $0.001 per share
Shares outstanding
38M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
0
Holdings value
$0
Grand Portfolio weight change
-0.001%
Number of holders
0
Number of sells
-129
Average Value change %
0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EcoR1 Capital, LLC 27.9% +86.7% $78.6M $36.4M 10.7M +86.5% EcoR1 Capital, LLC May 15, 2025
BlackRock Portfolio Management LLC 6.1% $13.2M 2.33M BlackRock Portfolio Management LLC Mar 31, 2025
BlackRock, Inc. 5.7% $12.3M 2.18M BlackRock, Inc. Mar 31, 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% -50% $15.7M -$14.9M 2.13M -48.7% RA Capital Management, L.P. May 15, 2025
MPM BioVentures 2014, L.P. 4.7% $10.2M 1.8M ANSBERT GADICKE May 13, 2025
TANG CAPITAL MANAGEMENT LLC 100% +900% $102K -$39M 10K -99.7% TANG CAPITAL MANAGEMENT, LLC Aug 29, 2025

Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 0 $0 -$376M 0
2025 Q2 37.8M $377M +$70.8M $9.97 134
2025 Q1 37M $221M +$13M $5.97 128
2024 Q4 34.1M $262M -$45.4M $7.68 133
2024 Q3 36.6M $373M -$1.63M $10.21 146
2024 Q2 36.2M $537M +$29.4M $14.84 132
2024 Q1 34.2M $466M -$7.32M $13.64 126
2023 Q4 80.2K $879K +$636K $10.95 2
2023 Q3 35.5M $389M +$6.64M $10.95 141
2023 Q2 34.5M $457M -$19.2M $13.24 140
2023 Q1 36M $489M -$8.81M $13.61 149
2022 Q4 36.2M $707M -$15.8M $19.53 144
2022 Q3 35.6M $677M -$16.1M $19.05 131
2022 Q2 35.3M $723M -$10.9M $20.60 143
2022 Q1 35.1M $1.13B +$60.2M $32.18 149
2021 Q4 32.6M $1.52B +$93.9M $46.56 113
2021 Q3 31M $837M +$54M $27.00 75
2021 Q2 29.4M $753M -$19.7M $25.65 81
2021 Q1 30.1M $1.03B +$90.2M $34.18 75
2020 Q4 25.8M $870M +$60.3M $33.82 69
2020 Q3 24.5M $604M +$546M $24.67 53